Boundless Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BOLD research report →
Price Chart
About the company
Boundless Bio, Inc. , a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA).
- CEO
- Zachary Hornby
- IPO
- 2024
- Employees
- 28
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on BOLD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $64.95M
- P/E
- -1.01
- PEG
- -0.85
- P/S
- 0.00
- P/B
- 0.98
- EV/EBITDA
- -0.76
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -70.89%
- ROIC
- -103.08%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,251,000-15.2%
- Op Income
- $-63,552,000
- Net Income
- $-58,197,000+11.0%
- EPS
- $-2.60+32.5%
- OCF Growth
- +23.3%
- FCF Growth
- +25.5%
- 52W High
- $3.01
- 52W Low
- $0.96
- 50D MA
- $2.38
- 200D MA
- $1.54
- Beta
- 0.38
- RSI (14)
- 72
- Avg Volume
- 1.29M
No earnings-call transcripts are available for BOLD yet.
- Free Float
- 76.7%
- Shares Outstanding
- 22.47M
- Float Shares
- 17.23M
of shares held by institutions
35 13F filers
Buy/sell ratio 4.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 662.76K | ▲ 93.10K |
| Cwm, LLC | 8 | ▲ 8 |
Held by 22 ETFs
Biggest fund positions in BOLD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 21, 26 | TANG KEVIN | buy | 2,975 |
| Jul 20, 26 | TANG KEVIN | buy | 1,623 |
| Jul 17, 26 | TANG KEVIN | buy | 265 |
| Jul 16, 26 | TANG KEVIN | buy | 18,491 |
| Jul 15, 26 | TANG KEVIN | buy | 1,600 |
| Jul 14, 26 | TANG KEVIN | buy | 43,878 |
| Jul 13, 26 | TANG KEVIN | buy | 48,211 |
| Jul 10, 26 | TANG KEVIN | buy | 43,367 |
| Jul 9, 26 | TANG KEVIN | buy | 7 |
| Jul 8, 26 | TANG KEVIN | buy | 14,338 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BOLD coverage
Recent articles, reports, and earnings notes.
No research on BOLD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BOLD report →Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders
globenewswire.com · Jul 2
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?
gurufocus.com · Jun 25
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)
gurufocus.com · Jun 23
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)
prnewswire.com · Jun 23
BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders
businesswire.com · Jun 23
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
globenewswire.com · Jun 23
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
globenewswire.com · May 8
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
globenewswire.com · Apr 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.